{"filings":[{"id":141285,"accession_number":"0001104659-25-071716","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HOOKIPA shareholders approve asset sale to Gilead and company dissolution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Asset sale to Gilead Sciences approved: 5,063,462 for, 239,595 against, 1,502 abstain.","Plan of liquidation and dissolution approved: 4,969,875 for, 329,803 against, 4,881 abstain.","Adjournment proposal approved: 5,110,153 for, 191,383 against, 3,023 abstain.","Special meeting held July 29, 2025; 54.13% of outstanding shares voted.","Company will proceed with dissolution following asset sale closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141284,"accession_number":"0001104659-25-069029","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA plans voluntary delisting and deregistration ahead of asset sale to Gilead and dissolution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intends to voluntarily delist from Nasdaq; Form 25 expected July 29, delisting effective ~August 8, 2025.","Will file Form 15 to deregister under Section 12(g) and suspend SEC reporting after delisting.","Delisting/deregistration tied to pending asset sale to Gilead for HB-400/HB-500 programs and planned dissolution.","Special meeting of stockholders set for July 29, 2025 to approve asset sale and dissolution.","Upon dissolution, proceeds from asset sale and other assets to be distributed to stockholders after liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159097,"accession_number":"0001104659-25-051841","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","1.02","5.02","8.01","9.01"],"status":"ready","headline":"HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.","Board approved dissolution of HOOKIPA; filing of Certificate of Dissolution expected after Transfer Plan completion.","Asset sale and dissolution require stockholder approval; proxy statement to be filed for special meeting.","CEO Malte Peters receives severance, accelerated equity vesting, and a Special Dissolution Success Bonus up to €482,591.","Collaboration Agreement and Stock Purchase Agreement with Gilead will terminate at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177546,"accession_number":"0001104659-25-015647","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA abandons plan to acquire Poolbeg Pharma; issues Rule 2.8 no-offer statement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HOOKIPA board decides not to proceed with all-share acquisition of Poolbeg Pharma announced on Jan 2, 2025.","Announcement made under UK Takeover Code Rule 2.8; HOOKIPA reserves right to reverse under certain conditions.","Discussions for combination have ceased; no firm offer was made.","Financial adviser Moelis & Company advised HOOKIPA on the potential deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177545,"accession_number":"0001104659-25-007015","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HOOKIPA files Section 205 petition to validate 2022/2023 stockholder actions due to record date errors; hearing Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date for 2022 annual meeting was 78 days before the meeting (April 13 vs. June 30, 2022), violating DGCL 60-day limit.","Record date for 2023 annual meeting was 66 days before the meeting (April 4 vs. June 9, 2023), also noncompliant.","Petition seeks validation of 2022 share increase (100M to 200M shares), plan amendment, and director elections from both meetings.","As of April 2024, over 36.6M shares may be invalid if 2022 amendment is not validated, affecting subsequent corporate actions.","Delaware Chancery Court will hold final hearing on Feb 14, 2025; stockholders may appear or submit written positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177544,"accession_number":"0001104659-25-002517","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA and Poolbeg update: Gilead to invest up to $8.75M in potential combination fundraise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead intends to vote consistent with HOOKIPA board recommendation if a formal offer is made.","Gilead to participate in concurrent Fundraise up to $8.7495 million, consistent with existing obligations.","Discussions remain non-binding and non-exclusive; no assurance of a firm offer or transaction completion.","Update follows prior announcements on January 2 and January 7, 2025 regarding the potential combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177543,"accession_number":"0001104659-25-001553","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA reports Gilead support for potential Poolbeg acquisition; fundraise revised to $30M+ primary placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead, owning 19.4% of HOOKIPA shares, signals intent to vote for the deal and join the $30M+ fundraise.","HOOKIPA revised fundraise to ~$30M+ primary private placement (previously up to ~$30M).","Oppenheimer & Co. Inc. engaged as placement agent for the private placement fundraise.","Discussions remain non-binding; no assurance a firm offer will be made or deal completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177542,"accession_number":"0001104659-25-000020","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA announces non-binding discussions to acquire Poolbeg Pharma in all-share deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Poolbeg shareholders to receive 0.03 HOOKIPA shares per share; expected ~55% ownership of combined entity before planned $30M fundraise.","Combined group to be Nasdaq-listed with operations in EU, UK, and US; Poolbeg to delist from AIM.","CVR for HOOKIPA shareholders tied to Gilead milestones (up to $407.5M) and HB-200 proceeds.","PUSU deadline under UK Takeover Code set for 30 January 2025; no certainty a firm offer will be made.","Fundraise of up to $30M to extend cash runway through year-end 2026, concurrent with deal completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194261,"accession_number":"0001104659-24-121019","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.","Pauses eseba-vec program; early termination of Phase 1/2 trial for HPV16+ head and neck cancers (not due to safety or efficacy).","Focuses on phase 1-ready HB-700 for KRAS mutated cancers (lung, colorectal, pancreatic); FDA IND clearance received Apr 2024.","Continues HB-500 (HIV) Phase 1b trial and HB-400 (Hepatitis B) program with partner Gilead.","Will seek partnering opportunities for the eseba-vec program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194260,"accession_number":"0001558370-24-015708","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.","Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.","Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.","First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.","Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10."],"consensus_eps_estimate":-1.3036,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":42592000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210588,"accession_number":"0001104659-24-095236","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma: two directors resign; Julie O'Neill appointed Non-Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan van de Winkel and Tim Reilly resign effective Aug 30, 2024, citing increased time commitments from other roles.","Julie O'Neill appointed Non-Executive Chair; Board reduced from 6 to 5 members.","Board reclassified into three classes; O'Neill reappointed as Class I director, term expiring at 2026 Annual Meeting.","Audit Committee: Cassidy (Chair), Kaufman, O'Neill; Compensation: O'Neill (Chair), Cassidy; Nominating: Kaufman (Chair), Cassidy.","Resignations not due to any disagreement with Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210587,"accession_number":"0001558370-24-011626","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.","Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.","Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.","Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.","Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND."],"consensus_eps_estimate":-1.2776,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":37889000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210586,"accession_number":"0001104659-24-083019","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","7.01","1.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma appoints Dr. Malte Peters CEO and Terry Coelho CFO; launches strategic review for HB-200","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.","Terry Coelho appointed EVP & CFO effective July 22, 2024; salary $480k, signing bonus $240k, RSU $450k.","Former CEO Jörn Aldag and CFO Reinhard Kandera separated July 22, resigned from board July 23.","Sean Cassidy appointed independent director and Audit Committee chair effective July 22.","Company launches strategic review to focus on HB-200 and create shareholder value; no impact on operations or trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210585,"accession_number":"0001104659-24-078760","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"HOOKIPA Pharma completes 1-for-10 reverse stock split, effective July 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-10 reverse split effective 5:00 p.m. ET on July 9, 2024; par value unchanged at $0.0001.","Authorized shares reduced from 400M to 40M; fractional shares cashed out.","Outstanding shares reduced from ~96.6M to ~9.7M immediately after split.","Conversion ratios/exercise prices adjusted for convertible preferred stock, stock options, and equity plans.","Reverse split was previously disclosed and affects all stockholders uniformly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228925,"accession_number":"0001104659-24-072792","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"HOOKIPA shareholders approve doubling authorized shares and authorize reverse split","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 200M to 400M shares; approved by 64.8M for, 3.4M against.","Shareholders authorized board to implement reverse stock split (1:2 to 1:10) before June 17, 2025; 63.4M for, 4.7M against.","Directors Timothy Reilly and Malte Peters elected to Class II with 51.9M and 53.9M votes respectively.","Ratification of PwC Wirtschaftsprüfung GmbH as independent auditor for FY2024 approved (67.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228924,"accession_number":"0001104659-24-068248","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.","In CPS≥20 subgroup (N=17, registrational target): ORR 53%, CR 18%, DCR 82%; PFS 16.3 mo, OS rate 88% at 9 mo.","HB-200 + pembrolizumab well-tolerated; Grade≥3 TRAEs in 15%, no treatment-related deaths.","Company plans to begin pivotal Phase 2/3 trial in Q4 2024 with FDA alignment on path to accelerated approval.","Data presented as oral abstract at ASCO 2024; median follow-up for CPS≥20 subgroup was 8.4 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228923,"accession_number":"0001104659-24-064762","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.","Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.","Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.","HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228922,"accession_number":"0001558370-24-007462","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.","Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.","HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.","HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.","Mark Winderlich appointed Chief Development Officer effective April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":36599000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228921,"accession_number":"0001104659-24-051581","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HOOKIPA announces pivotal Phase 2/3 trial design for HB-200 in combo with pembrolizumab; FDA alignment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pivotal Phase 2/3 trial for HB-200 + pembrolizumab in first-line HPV16+ recurrent/metastatic OPSCC; FDA alignment achieved.","Trial expected to enroll ~250 patients; Phase 2 primary analysis in 2026 with potential accelerated approval filing.","First patient enrollment anticipated in Q4 2024.","HB-200 abstract accepted as oral presentation at ASCO 2024 with data from ~40 patients in head and neck cancer.","Company also received PRIME designation from EMA for HB-200 in combination with pembrolizumab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247560,"accession_number":"0001558370-24-003735","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.","Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.","Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.","HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.","Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247559,"accession_number":"0001104659-24-008825","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"HOOKIPA Pharma transfers listing to Nasdaq Capital Market to regain bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq approval to transfer common stock listing from Global Select Market to Capital Market effective Feb 1, 2024.","Granted a second 180-day compliance period until July 29, 2024 to meet $1.00 minimum bid price requirement.","Company must close at $1.00 per share for 10 consecutive business days to regain compliance.","If compliance not achieved by July 29, 2024, Nasdaq may delist the stock; Company may appeal.","Company intends to cure deficiency via a reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247558,"accession_number":"0001104659-24-007471","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["1.02","2.02","7.01","2.05","2.06","9.01"],"status":"ready","headline":"HOOKIPA reports Roche termination of HB-700 deal, 30% workforce cut, $117.5M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche terminates collaboration for HB-700 (KRAS-mutated cancers) effective April 25, 2024; HOOKIPA regains full rights and remains eligible for IND milestone payment.","Workforce reduction of ~30% (55 employees) approved; expected severance costs ~$1.5M, non-cash impairment of GMP facility $10M-$13M.","Company to prioritize HB-200 (HPV16+ HNSCC) and Gilead-partnered infectious disease programs; pauses HB-300 and most preclinical research.","Preliminary cash and equivalents of $117.5M as of Dec 31, 2023 (unaudited); company expects to conserve resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265024,"accession_number":"0001104659-23-127949","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Gilead invests $21.25M in HOOKIPA for 15M shares at $1.4167 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead purchased 15M shares for ~$21.25M at $1.4167/share; now holds 19.4% of HOOK outstanding stock.","HOOKIPA may sell up to $8.75M additional shares to Gilead in future equity raises under same agreement.","Funds to advance HIV therapeutic vaccine HB-500 through Phase 1; trial expected to start H1 2024.","Agreement replaces 2022 stock purchase agreement; total committed $30M now largely funded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265023,"accession_number":"0001104659-23-122878","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"HOOKIPA Pharma designates Dr. Roman Necina as Chief Operations Officer effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Roman Necina, formerly Chief Development Officer, appointed Chief Operations Officer.","Title change effective January 1, 2024; his existing employment contract remains unchanged.","Necina served as Chief Development Officer since July 2022 and previously as Chief Technology Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265022,"accession_number":"0001558370-23-018410","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.","Net loss of $19.1M vs $18.3M YoY; R&D expenses increased to $24.6M from $18.3M.","Cash and equivalents $108.1M as of Sep 30, 2023, down from $113.4M at Dec 31, 2022.","HB-200 + pembro achieved 42% ORR in 19 evaluable CPI-naïve patients, doubling historical 19% for pembro alone.","Anticipated milestones: Phase 2 HB-200 data H1 2024, randomized trial mid-2024; IND filings for HB-700 (H1 2024) and HB-500 (Q4 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":12722000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265021,"accession_number":"0001104659-23-110474","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"HOOKIPA Pharma COO Christine Baker resigns; role will not be filled","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Operating Officer Christine Baker resigned effective Oct 16, 2023; departure from company Jan 15, 2024.","Garden leave period from Nov 1, 2023 to Jan 15, 2024.","Company will not replace COO; responsibilities assumed by other management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282207,"accession_number":"0001104659-23-100256","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HOOKIPA CMO Schlienger resigns; Board member Dr. Peters named interim clinical lead","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Dr. Katia Schlienger resigns effective September 30, 2023 to pursue new opportunities.","Board member Dr. Malte Peters, former MorphoSys R&D head, appointed Senior Clinical Advisor ad interim.","CEO reaffirms focus on HB-200 randomized trial, HB-300 prostate program, and Roche/Gilead collaborations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282206,"accession_number":"0001558370-23-014390","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.","Cash $136.0M at June 30, 2023, up from $113.4M at Dec 31, 2022, after $50M June offering.","Phase 2 HB-200 + pembrolizumab: 43% ORR in CPI-naïve patients, double pembrolizumab alone; randomized trial planned H1 2024.","R&D expenses rose $3.6M to $19.7M on higher clinical costs for HB-200, HB-300, and partnered programs.","Exchange offer for 627,632 underwater options (exercise >$6.50) to eligible non-executive employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":5855000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282205,"accession_number":"0001104659-23-087830","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"HOOKIPA Pharma receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Aug 3, 2023 due to closing bid price below $1.00 for 30 consecutive business days.","Non-compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on Global Select Market.","Automatic 180-day cure period until Jan 30, 2024; must have $1.00 closing bid for 10 consecutive days.","If still non-compliant by Jan 30, 2024, may qualify for a second 180-day period if certain requirements met.","Evaluating options including reverse stock split; stock continues trading under \"HOOK\" with no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301357,"accession_number":"0001104659-23-070006","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Hookipa Pharma shareholders elect all three Class I director nominees and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joern Aldag elected with 23,467,198 For vs 694,812 Withhold; 12.6M broker non-votes.","Jan Van de Winkel elected with 22,299,220 For vs 1,862,790 Withhold; 12.6M broker non-votes.","David Kaufman elected with 23,856,771 For vs 305,239 Withhold; 12.6M broker non-votes.","Ratification of PwC as auditor passed: 35,649,440 For, 571,982 Against, 510,711 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301356,"accession_number":"0001104659-23-067170","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma prices $50M public offering of common & convertible preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 22,900,768 shares of common stock at $1.31/share and 15,268 Series A-2 convertible preferred shares at $1,310/share.","Gross proceeds of $50M; net proceeds expected ~$46.3M after underwriting discounts and expenses.","Offering expected to close June 5, 2023; joint book-runners are SVB Securities and RBC Capital Markets.","Each Series A-2 preferred share converts into 1,000 common shares, non-voting, with a beneficial ownership cap of 9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301355,"accession_number":"0001104659-23-066700","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA Phase 2 HB-200 data: 43% ORR with pembrolizumab vs 19% historical; pivotal trial planned for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.","Median overall survival of 14.2 months in heavily pre-treated monotherapy cohort (n=11, median follow-up 12.8 months).","Safety: 7% serious adverse events related to HB-200; 2% discontinuation rate across 132 patients.","Company preparing to start pivotal trial of HB-200 + pembrolizumab in 1st-line setting in 2024.","HB-200 induced rapid, sustained T-cell responses for at least 8 months associated with clinical benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301354,"accession_number":"0001558370-23-009248","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"HOOKIPA Q1 net loss $19.7M; cash $110M; milestones from Roche and Gilead; Phase 2 data on track for Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.","Cash $110.0M at March 31, 2023, down from $113.4M at Dec 31, 2022; used in operations partly offset by collaboration funds.","Achieved $10M milestone from Roche for HB-700 (KRAS-mutated cancers) and $5M from Gilead for HB-400 (chronic hepatitis B).","Phase 2 data for HB-200 in HPV16+ head and neck cancer with pembrolizumab expected in Q2 2023; Phase 1 trials initiated for HB-300 and HB-400.","Appointed Terry Coelho to Board of Directors; preclinical data presented at AACR on arenaviral combo with Roche's PD1-IL2v."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":3176000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301353,"accession_number":"0001104659-23-045006","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Michael A. Kelly resigns; Board adopts 2023 Inducement Plan reserving 500,000 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Michael A. Kelly resigned effective April 7, 2023, not due to any disagreement with the Company.","Terry Coelho appointed Chair of Audit Committee to fill vacancy; deemed audit committee financial expert.","Board approved 2023 Inducement Plan reserving 500,000 shares of common stock for new employee inducement grants.","Awards under the plan limited to employees commencing employment, per Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321185,"accession_number":"0001558370-23-003776","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.","Q4 revenue $7.8M, full-year $14.2M (down from $18.4M); net loss $64.9M for 2022 vs $75.7M in 2021.","HB-200 Phase 2 data (with pembrolizumab) due 2Q2023; HB-300 trial open; HB-700 IND planned 1H2024.","Roche collaboration: $10M milestone Feb 2023; potential milestones up to $930M plus royalties.","Gilead HBV milestone $5M Jan 2023; HIV program IND expected 2023; HB-101 program discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321184,"accession_number":"0001104659-23-031786","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA appoints Terry Coelho to Board of Directors effective April 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry Coelho appointed as Class III director, serving until the 2025 annual meeting.","She will serve on both the Audit Committee and Compensation Committee.","Ms. Coelho has over 35 years experience, including CFO roles at CinCor, BioDelivery Sciences, and Balchem.","Compensation includes an initial option for 19,200 shares, $40,000 annual cash retainer, plus committee retainers.","No other material arrangements or transactions exist with the new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321183,"accession_number":"0001104659-23-005397","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"HOOKIPA Pharma receives Nasdaq non-compliance notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Jan 17, 2023: bid price below $1.00 for 30 consecutive business days.","180-day cure period until July 17, 2023 to regain compliance by closing at $1.00 for 10 days.","Company evaluating options including reverse stock split authorized at June 2022 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339282,"accession_number":"0001104659-22-127337","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA appoints Katia Schlienger as CMO and Malte Peters to board effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katia Schlienger promoted to CMO effective Jan 1, 2023; previously EVP Clinical R&D since July 2022.","Malte Peters appointed to Board of Directors effective Jan 1, 2023; retiring as MorphoSys Chief R&D Officer at end of 2022.","Schlienger spent 14 years at Merck & Co. in oncology and vaccine development.","Peters previously held leadership roles at Novartis Oncology, Sandoz, and Micromet; also on Tango Therapeutics board.","Peters receives initial option for 19,200 shares, $40k annual cash retainer, and stock awards per non-employee director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339281,"accession_number":"0001558370-22-017561","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).","Cash $100.7M as of Sep 30, 2022 (up from $66.9M Dec 2021); excludes $25M Roche upfront and up to $30M Gilead stock purchase.","Entered Roche collaboration for HB-700 (KRAS-mutated cancers) and second candidate; $25M upfront, potential $930M milestones plus royalties.","FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer); Phase 1 start expected Q1 2023.","Phase 2 HB-200 + pembrolizumab data expected H1 2023; >20 patients dosed, enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":6421000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339280,"accession_number":"0001104659-22-110103","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"HOOKIPA signs collaboration with Roche for KRAS-mutated cancer therapy; $25M upfront, up to $930M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.","Roche licenses HB-700, an arenaviral immunotherapy for KRAS-mutated cancers; HOOKIPA conducts research through Phase 1b.","Roche obtains an exclusive option to license a second undisclosed arenaviral immunotherapy for an additional $15 million payment.","Tiered royalties of high single-digit to mid-teens percent on worldwide net sales for both programs upon commercialization.","First oncology licensing collaboration for HOOKIPA; partnership validates its arenavirus platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356656,"accession_number":"0001558370-22-013170","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA Q2 2022 revenue $2.7M, net loss $16.4M; FDA accepts IND for HB-300, HB-200 Phase 2 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.7M, down from $5.4M YoY due to lower cost reimbursements from Gilead collaboration.","Net loss $16.4M versus $17.2M in Q2 2021; R&D expenses decreased to $16.1M from $19.6M.","Cash, equivalents and restricted cash $118.9M at June 30, 2022, up from $66.9M at Dec 31, 2021.","FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer) and Drug Master File for platform.","HB-200 Phase 1 met all endpoints; Phase 2 started; initial data with pembrolizumab expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":4191000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356655,"accession_number":"0001104659-22-076551","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-07-01T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"HOOKIPA shareholders approve doubling authorized shares to 200M and reverse split range","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 100M to 200M via Certificate of Amendment.","Shareholders authorized reverse stock split in range of 1-for-2 to 1-for-10, if board elects.","Class III directors Julie O'Neill and Reinhard Kandera elected for three-year terms.","Stockholders ratified PwC Wirtschaftsprüfung GmbH as auditor for FY 2022.","2019 Stock Incentive Plan amended to increase authorized shares by 1M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375115,"accession_number":"0001104659-22-073084","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA CMO resigns; Schlienger and Necina promoted effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Igor Matushansky resigns effective June 30, 2022; will chair Scientific Advisory Board.","Katia Schlienger promoted to EVP Clinical Development, joins Executive Team.","Roman Necina appointed Chief Development Officer, integrating manufacturing and project management.","Gilead registration rights agreement filed; Gilead may purchase up to $35M in common stock; initial $5M at $3.00/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375114,"accession_number":"0001104659-22-068301","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.","56% of alternating 2-vector patients had target lesion shrinkage vs 38% for single-vector HB-201.","32% on alternating 2-vector had tumor-specific T cells >5% of circulating pool vs 7% on HB-201.","HB-200 well tolerated; only 8.8% grade ≥3 treatment-related side effects, mostly flu-like symptoms.","Phase 2 plans include combos with pembrolizumab; initial results expected H2 2022, randomized trial H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375113,"accession_number":"0001558370-22-008849","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.","Revenue $1.4M vs $5.3M Q1 2021; $19M in milestone/initiation fees deferred for future recognition.","R&D expenses $16.6M (down from $20.2M); net loss $18.0M vs $17.2M in prior-year quarter.","Gilead HIV program advanced: $4M milestone, $15M initiation fee, $35M equity commitment; up to $237M milestones plus royalties.","HB-200 Phase 1 data due mid-2022; Phase 2 combo with pembrolizumab data in 2H 2022; prostate cancer IND expected Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1445000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375112,"accession_number":"0001104659-22-054817","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HOOKIPA promotes Christine D. Baker to COO; base salary raised to $450,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Baker, previously Chief Business Officer since Aug 2019, becomes COO effective May 1, 2022.","Base salary increased to $450,000; target annual incentive set at 40% of base salary.","She will continue to drive strategic collaborations and US operations growth.","CEO Joern Aldag cites her role in securing major pharma partnerships for the arenavirus platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375111,"accession_number":"0001104659-22-047835","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HOOKIPA board member Lengauer to depart; appoints Timothy Reilly as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christoph Lengauer will not stand for re-election at June 30, 2022 annual meeting; departure not due to disagreement.","Timothy Reilly, Ph.D. appointed to board effective immediately; will serve as Class II director until 2024.","Reilly previously SVP at Bristol Myers Squibb, currently Chief Development Officer at HotSpot Therapeutics.","As non-employee director, Reilly receives initial option for 19,200 shares plus annual $40,000 cash retainer.","Reilly will join Nominating and Corporate Governance Committee on June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393504,"accession_number":"0001558370-22-004208","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.","Pro-forma cash of $156.9M (Dec 31, 2021) reflects $35M Gilead equity, $15M fee, and $70M follow-on proceeds.","Gilead HIV program advanced, triggering $54M commitment; $4M milestone, $15M fee, $35M equity at premium.","HB-200 Phase 2 combo with pembrolizumab in HNSCC dosed Jan 2022; initial data expected H2 2022.","Klaus Orlinger promoted to CSO; executive team accepted 50% of 2021 bonus in options at $3/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393503,"accession_number":"0001104659-22-030112","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma prices $75M public offering of common stock and convertible preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 21.7M common shares at $2.00/share and 15,800 Series A-1 convertible preferred shares at $2,000 each (each convertible into 1,000 common shares).","Gross proceeds $75M; net proceeds expected ~$70M after underwriting discounts and expenses.","Offering expected to close March 4, 2022; underwriters have 30-day option for up to 5.625M additional common shares.","After offering, shares outstanding will be 50,868,668, excluding the underwriters' option.","SVB Leerink and RBC Capital Markets acted as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393502,"accession_number":"0001104659-22-028669","cik":1760542,"company_name":"HOOKIPA Pharma Inc.","ticker":"HOOK","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HOOKIPA Pharma announces proposed public offering of common and non-voting convertible preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes shares of common stock and Series A non-voting convertible preferred stock in an underwritten public offering.","Underwriters granted 30-day option to purchase up to an additional 15% of shares offered, including underlying common stock.","SVB Leerink and RBC Capital Markets are joint book-running managers for the offering.","Company simultaneously terminated its ATM prospectus supplement with SVB; no ATM sales until new supplement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14549760.05128205,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-01T23:59:59+00:00|393502"}